PROGRAMME

Thursday, 25th May 2017

16:00 Registration

16:45 SYMPOSIUM
LATE COMPLICATIONS OF DIABETIC EYE DISEASE
Danubius Health Spa Resort Margitsziget, Budapest

16:45 Welcome and introductions
Chaired by: Associate Professor Tamas Varkonyi and Professor Andrea Facsko

17:00 Associate Professor Tamas Varkonyi, Hungary
The diabetologist’s view: treating diabetes in people with late complications

17:15 Professor Reinier Schlingemann, Netherlands
Diabetic macular oedema: treatment paradigms for chronic presentation

17:30 Associate Professor Miklos Resch, Hungary
Advanced diabetic retinopathy

17:45 Professor Zsolt Biro, Hungary
The diabetic cataract: when to operate?

18:00 Summary and meeting close

The official programme of EASDec starts.
Danubius Health Spa Resort Margitsziget, Budapest

18.30-20.00
Opening ceremony with light refreshments and finger food
Opened by Professors Andrea Facsko and Simon Harding

Venue: Danubius Health Spa Resort Margitsziget
Friday, 26th May 2017

08.00 Registration

09.00 INTRODUCTION AND WELCOME
Professor Simon Harding, UK

SESSION 1: NEW APPROACHES FOR TREATING DIABETIC RETINOPATHY
Chaired by: Professors Rafael Simo and Jakob Grauslund

09.15 Hernández, C (Spain)
Topical administration of dipeptidyl peptidase iv (DPP-IV) inhibitors prevents retinal neurodegeneration in experimental diabetes

09.30 Canning, P (Ireland)
Neuroprotective efficacy of ARA290, an erythropoietin derived peptide, in diabetic retinopathy

09.45 Beltramo, E (Italy)
Diabetic-like conditions modulate the expression of thiamine transporters in human retinal cells

10.00 Hu, TT (Belgium)
Targeting placental growth factor attenuates retinal permeability and inflammation in diabetic Akimba mice

10.15 Weksler-Zangen, S (Israel)
The Cohen diabetic rat an in-vivo model of diabetic retinopathy

10.30 Vilà-González, M (UK)
Functional human IPS-ECS from diabetic patients provide a basis for in vitro modelling of diabetic retinopathy

10.45 Coffee/Tea Break

SESSION 2: NEURODEGENERATION AND BIOMARKERS
Chaired by: Professor M. Porta and Dr. I. Klaassen

11.25 Simó, R (Spain)
Topical administration of somatostatin and brimonidine in the early stages of diabetic retinopathy: results of the eurocondor study

11.45 Costa, M (Portugal)
Retinal layer location of increased retinal thickness and retinal thinning on the cohort of the EUROCONDOR clinical trial

12.00 Csutak, A (Hungary)
Two-years Follow up of Corneal Microstructural Changes in Patients with Type 1 Diabetes

12.15 Ecsedy, M, E (Hungary)
Variant SDF1-3’(801)A carriers are in increased risk for diabetic maculopathy

12.30 Cunha-Vaz, J (Portugal)
Diabetic retinopathy phenotypes of progression to macular oedema. Pooled analysis from independent longitudinal studies of up to two years duration

12.45 Lunch (poster presenters have priority)

SESSION 3: POSTER SESSION

13.15 Poster presenters at poster, as moderators will visit

14.15 Tea/coffee served as poster presenters circulate
INVESTIGATION AND IMAGING
Moderated by: Professor Jose Cunha-Vaz and Drs. Vivian Schreur

1. **Blindbæk, S (Denmark)**
   Changes in retinal oxygen saturation after intravitreal aflibercept in patients with diabetic macular oedema.

2. **Deák, K (Hungary)**
   Electrophysiological methods for the detection of subclinical stage retinal and optic nerve involvement in diabetes.

3. **Horváth, H (Hungary)**
   Choroidal thickness and diabetic retinopathy assessed by swept-source optical coherence tomography in patients with diabetes.

4. **Santos, A (Portugal)**

5. **Soares, M (Portugal)**
   Quantification of retinal microvascular density in diabetic patients using cirrus angioplex optical coherence tomography angiography (OCTA).

6. **Lattanzio, R (Italy)**
   Preclinical retinopathy in T1DM: screening in paediatric age.

7. **Szalay, L (Hungary)**
   Early detection of diabetic angiopathy based on the automated analysis of the Optovue RTVue XR 100 Avanti® angio-OCT recordings.

8. **Cakir, B (Turkey)**
   Corneal epithelial thickness in patients with type 2 Diabetes Mellitus.

LABORATORY SCIENCE
Moderated by: Professors Cristina Hernandez and Paul Canning

9. **Klaassen, I (Netherlands)**
   Identification of proteins associated with clinical and pathological features of proliferative diabetic retinopathy.

10. **Huang, Y (Taiwan)**
    Highly regulator of cell cycle (RGCC) protein expression in diabetic retinopathy.

11. **Sergeys, J (Belgium)**
    Thorough longitudinal in vivo characterization of the streptozotocin-induced diabetic mouse model.

EPIDEMIOLOGY AND RISK FACTORS
Moderated by: Dr. Amber van der Heijden and Dr. Gabor Toth

12. **Pék, A (Hungary)**
    Cataract - diabetes coexistence based on RAAB study in Hungary.

13. **Tomić, M (Croatia)**
    Inflammation and obesity: possible link to the pathogenesis of retinopathy in type 2 but not in type 1 diabetes.

14. **Oliveira, C (Portugal)**
    RetmarkerDR computed MA Formation Rate as a predictor of DR progression to diabetic macular oedema. Pooled analysis from different longitudinal studies of up to two years duration.

15. **Torp, T (Denmark)**
    Changes in retinal arterial geometry in relation to activity of proliferative diabetic retinopathy 6 months after panretinal photocoagulation.
16. **Gooding, K (UK)**
Examining longitudinal changes of macular thickness in the early stages of diabetic retinopathy

17. **Blows, P (UK)**
The next steps for the DR-NET: a Network to Tackle the Burden of Diabetic Retinopathy in 13 Low- and Middle-Income Countries

**SCREENING AND AUTOMATION**
Moderated by: **Dr. Frank Verbraak and Professor Dorottya Szabo**

18. **Antal, B (Hungary)**
Data analysis applied to diabetic retinopathy screening: performance evaluation

19. **Bhaskaranand, M (USA)**
ETDRS 7-field Stereoscopic Reference Standard for Clinical Validation of Automated DR screening on 2-field Monoscopic Images

20. **D’Souza, Y (UK)**
The diabetic eye screening service goes green in Manchester, UK

21. **Tavakoli, M (UK)**
Implementation of corneal confocal microscopy for screening diabetic neuropathy in primary care: a feasibility and acceptability study

22. **Jones, C (UK)**
Outcomes of referrals from diabetes eye screening to a slit lamp biomicroscopy clinic

23. **Creer, R (UK)**
The introduction of the diabetic passport within ophthalmology clinics at Manchester Royal Eye Hospital: Patient opinion and perceived benefits

24. **Harding, S (UK)**
Safety of individualised variable interval screening for referable diabetic retinopathy – baseline data from the ISDR randomised controlled study

25. **Ramachandra, C (USA)**
Automated longitudinal analysis of retinal fundus images with applications to screening intervals and risk stratification

26. **Ibanez-Bruron, M (UK)**
How well integrated is the ophthalmic care for children and young people living with diabetes in England?

27. **Scanlon, P (UK)**
Diabetic retinopathy screening in china

28. **Byrne, P (UK)**
Putting patients’ eyes back into their bodies: implications of a social science study of screening and diabetes eye care

**CLINICAL PRACTICE**
Moderated by: **Professors Andrea Facsko and Morten B. Hansen**

29. **Lopez Galvez, M (Spain)**
Clinical practice in the management of diabetic macular oedema. Results from a retinologists national survey

30. **Doğan, E (Turkey)**
Outcomes of repeated intravitreal dexamethasone implant for the treatment of ranibizumab- resistant diabetic macular oedema

31. **Mohite, A (UK)**
Does the start of intravitreal anti-VEGF treatment for the management of diabetic macular oedema result in better diabetes control? A 2-year follow-up study
32. **Jasani, K (UK)**  
A retrospective review of clinical outcomes of intravitreal Aflibercept for diabetic macular oedema (DMO) in treatment naïve patients with those switched from alternative therapies over 12 months at Manchester Royal Eye Hospital (MREH)

33. **Ba-Ali, S (Denmark)**  
Salivary melatonin concentrations in type-1 and type-2 diabetes mellitus

34. **Peto, T (UK)**  
ILUVIEN (fluocinolone acetonide [FAc]) in the management of chronic diabetic macular oedema (DMO) – assessing the need for additional therapies in clinical practice.

**SESSION 4**  
Chaired by: **Professors Simon Harding and Andrea Facsko**

**15:15 EVA KOHNER LECTURE**  
Steve Aldington: *I've looked at life from both sides now*"  
Introduced by **Professor Simon Harding**

16.00 **Gábor Tóth, (Hungary)**  
Diabetes and diabetic retinopathy in people aged 50 and older in Hungary

16.15 **Morten B. Hansen (UK)**  
Diabetic retinopathy in Europe – Results of the E3 Consortium Diabetes Group

16:30 **Keynote lecture: Professor Andrea Facsko**  
Treating advanced diabetic eye disease

16:50 10 minutes discussion

**17.00 ANNUAL GENERAL MEETING**  
Moderator: **Professor Reinier Schlingemann**

**19.00 CONFERENCE RECEPTION AND DINNER**  
Meet at Reception of Danubius Grand Hotel Margitsziget, Budapest, details tbc
Saturday 27th May 2016

08.30 Registration

SESSION 5: EARLY DETECTION AND TECHNOLOGY IN SCREENING
Chaired by: Professors Tunde Peto and Simon Harding

09.00 Verbraak, F (Netherlands)
Real life evidence of improved automated detection of diabetic retinopathy through integration of deep learning.

09.15 Van der Heijden, A (Netherlands)
Prediction models for the risk of retinopathy in people with type 2 diabetes. A systematic review

09.30 Stratton, I (UK)
Uptake of diabetic eye screening - are some domains of deprivation more important than others?

09.45 Szabo, D (Hungary)
Telemedical diabetic retinopathy screening in Hungary

10.00 Dupas, B (France)
Decreased macular flow density is associated with visual impairment in patients with florid diabetic retinopathy

10.15 Palarie, N (Moldova)
Role of optical coherence tomography in diabetic macular oedema screening

10.30 Coffee/Tea Break

SESSION 6: DIABETES INDUCED RETINAL INFLAMMATION
Chaired by: Professors Reinier Schlingemann and Rózsa Dégi

11.10 Keynote Speaker: Assoc.Prof. Dégi, R (Hungary)
Retinal dysfunction due to inflammation caused by diabetes

11.40 Tecilazich, F (USA)
Patroller Monocytes protect retinal microvessels from diabetes

11.55 Solà-Adell, C (Spain)
Calcium dobesilate prevents the oxidative stress and inflammation induced by diabetes in the retina of db/db mice

12.10 Van der Wijk, A (Netherlands)
Corticosteroids induce barrier properties of the blood-retinal barrier via direct effects on the endothelium

12.25 Mazzeo, A (Italy)
Somatostatin protects human retinal pericytes from microglia-mediated inflammation

12.40 Schreur, V (Netherlands)
Hyperreflective foci predict treatment response to bevacizumab in patients with diabetic macular oedema

13.00 Best poster prize ceremony and closing remarks
Professor Simon Harding, UK